Globalspace Technologies Limited's board has approved the acquisition of an additional 99.83% stake in its subsidiary, Miljon Mediapp Private Limited, through the conversion of a loan amounting to ₹12.64 crore into equity shares. The decision, aimed at strengthening control over the pharma-focused digital engagement platform, was taken during a board meeting held on June 18, 2026. The transaction is expected to be completed on or before July 31, 2026.

The acquisition involves converting an existing loan granted by the company into equity, resulting in a total cost of acquisition of ₹12.64 crore. This move is not classified as a related party transaction under Regulation 2(1)(zc) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No regulatory approvals are required for this conversion, which will increase the company's shareholding in Miljon Mediapp to 99.83%.

Miljon Mediapp operates within the Pharma Tech industry, providing a digital engagement ecosystem designed to connect pharmaceutical companies with healthcare professionals, patients, distributors, and field sales teams. The platform facilitates patient support programs, medication adherence initiatives, doctor engagement, and digital detailing. By utilizing real-time analytics and compliant digital workflows, the entity aims to assist pharmaceutical companies in improving therapy adoption and maximizing sales and marketing efficiency.

Financial disclosures regarding the target entity indicate a net worth of ₹31,97,000 as on March 31, 2026. The entity reported nil turnover for the fiscal years 2025-26 and 2024-25. Miljon Mediapp was converted into a company form from a Limited Liability Partnership (LLP) on March 29, 2025.

Acquisition Details

Globalspace Technologies held its Board of Directors meeting on Friday, May 15, 2026, via video conferencing, wherein the board considered and approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The meeting commenced at 04:26 P.M. and concluded at 08:30 P.M. The results were reviewed by the Audit Committee and taken on record by the board, with statutory auditors Bansilal Shah & Co. expressing an unqualified audit opinion on both standalone and consolidated financial statements. Subsequently, on May 17, 2026, the company filed an intimation with BSE Limited pursuant to Regulation 33 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming the publication of its audited financial results in Financial Express (English) and Mumbai Lakshadeep (Marathi).

Standalone Financial Performance

On a standalone basis, Globalspace Technologies reported a significant turnaround for the year ended March 31, 2026. The company posted a net profit after tax of ₹136.49 lacs compared to a net loss of ₹183.73 lacs in the previous year. Total income rose to ₹3,335.63 lacs from ₹2,933.02 lacs, driven by revenue from operations of ₹3,301.35 lacs versus ₹2,932.48 lacs previously. The following table summarises the key standalone financial metrics:

For the quarter ended March 31, 2026, standalone revenue from operations stood at ₹1,050.30 lacs, with net profit after tax of ₹88.18 lacs compared to ₹8.74 lacs in the corresponding quarter of the previous year.

Consolidated Financial Performance

On a consolidated basis, which includes subsidiaries Innopharma Healthcare Private Limited and Miljon Medi App Private Limited, the group reported consolidated revenue from operations of ₹5,146.92 lacs for the year ended March 31, 2026, compared to ₹4,304.58 lacs in the prior year. Consolidated net profit after tax stood at ₹285.23 lacs, reversing a loss of ₹199.92 lacs in the previous year. The key consolidated financials are presented below:

For the quarter ended March 31, 2026, consolidated revenue from operations was ₹1,604.49 lacs, with net profit after tax of ₹245.05 lacs against a loss of ₹15.48 lacs in the year-ago quarter.

Key Balance Sheet and Ratio Highlights

The standalone balance sheet as at March 31, 2026 reflects total assets of ₹6,512.21 lacs, with total equity of ₹5,588.34 lacs compared to ₹5,450.72 lacs in the prior year. On the consolidated front, total assets stood at ₹6,677.56 lacs with total equity of ₹5,695.00 lacs. Key financial ratios showed meaningful improvement, as detailed below:

The auditor's report also noted that an equity commitment towards M/s Miljon Medi App Pvt Ltd of ₹1,144.33 lacs is pending for share allotment in the books as on March 31, 2026.

Corporate Actions: CEO Appointment, Auditor Re-appointment, and ESOP Grant

In addition to the financial results, the board approved several significant corporate actions at the same meeting. The following key decisions were taken:

Ms. Tania Mazumdar is described as a dynamic pharmaceutical and digital health leader with over 22 years of experience across pharmaceutical, diagnostics, and health technology sectors, with expertise in strategic planning, business development, digital transformation, and stakeholder management. She is not related to any director of the company. M/s. Maheshwari Maheshwari & Co., established in 1988, is a Category-I Chartered Accountancy Firm headquartered in Mumbai with a branch in Indore, registered with ICAI (Reg. No. 105838W), CAG (Reg. No. BO0733), and RBI (Unique Code: 064394). The intimation was signed by Krishna Murari Singh, Managing Director, on May 15, 2026, in compliance with Regulation 30 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.